Dendreon’s (DNDN) big breakthrough prostate cancer treatment Provenge was supposed to be on its way to becoming a blockbuster product. Instead, Dendreon said Wednesday the drug badly missed a sales target for the second quarter, the company withdrew its revenue goal for the year and said it will cut jobs. Is DNDN dead in the water?
An acquisition of Immunocellular by Dendreon would ensure, in my opinion, that Dendreon remains the leader of both the “now” and “next” generation of cancer immunotherapeutic treatment, and it could also solve the cost issues behind the current manufacturing and logisitics of administering Provenge treatments.
With DNDN trading down by 60%, a lot of attention is going to be drawn to the company and the cancer immunotherapy sector as a whole.
It might be worth taking the time to entertain the possibilities.
Marketclub has a free stock analysis explaining how this news effects the stock. FREE DNDN Report here sent to your in-box.
